Taken together, our pharmacological screen demonstrates the involvement of TGF-β and JAK signaling in the paracrine crosstalk between luminal breast cancer cells and CAFs, and identify potential points of intervention for future combinatorial treatment regimens. The gene discussed is TGFB1; the disease is breast carcinoma.